EP2440235A1 — Glp-1 and fgf21 combinations for treatment of diabetes type 2
Assigned to Novo Nordisk AS · Expires 2012-04-18 · 14y expired
What this patent protects
The invention relates to the use of a Fibroblast Growth Factor 21 (FGF21 ) compound and a Glucagon-Like Peptide 1 (GLP-1 ) compound in combination for the preparation of a medicament for the treatment of diabetes, more in particular type 2 diabetes, as well as pharmaceutical comp…
USPTO Abstract
The invention relates to the use of a Fibroblast Growth Factor 21 (FGF21 ) compound and a Glucagon-Like Peptide 1 (GLP-1 ) compound in combination for the preparation of a medicament for the treatment of diabetes, more in particular type 2 diabetes, as well as pharmaceutical compositions comprising certain FGF21 and GLP-1 compounds in combination, together with a pharmaceutically acceptable carrier. The combination has a significant effect on parameters of relevance for diabetes type 2, viz. on the viability of beta cells ex vivo in the presence of free fatty acids, on caspase activity of beta cells ex vivo (a measure of cell apoptosis), and a blood glucose lowering effect on db/db mice in vivo .
Drugs covered by this patent
- Ozempic (semaglutide) · Novo Nordisk
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.